Stuart Essig - IDEXX Laboratories Independent Director
| IDXX Stock | USD 477.79 0.45 0.09% |
Director
Mr. Stuart M. Essig, Ph.D. serves as Independent Director of the IDEXX Laboratories, Inc. Dr. Essig has served as the Chairman of the Board of Directors of Integra LifeSciences Holdings Corporation since January 2012, and he first joined Integras Board of Directors in December 1997. In addition, Dr. Essig was Integras Chief Executive Officer from December 1997 until June 2012. Since 2012, he has also served as Managing Director of Prettybrook Partners LLC, a family office firm focused on investing in the healthcare industry. He is an Executive in Residence at Cardinal Partners and a Venture Partner at Wellington Partners Advisory AG, both VC firms, and a Senior Advisor to TowerBrook Capital Partners and Water Street Healthcare Partners. He serves as Chairman of the Board of Directors of privatelyheld Breg, Inc., and on the board of directors of Availity, LLC. Before joining Integra, Dr. Essig was a managing director in mergers and acquisitions for Goldman, Sachs and Co., specializing in the medical device, pharmaceutical and biotechnology sectors. Dr. Essig has also served on the executive committee, nominating and governance committee and as treasurer of ADVAMED, the Advanced Medical Technology Association. Dr. Essig holds an undergraduate degree from the Woodrow Wilson School of Public and International Affairs at Princeton University and a PhD in financial economics and an M.B.A. from the University of Chicago. As the former Chief Executive Officer of Integra LifeSciences Holdings Corporation and its current Chairman of the Board, Dr. Essig has extensive executive leadership experience in developing, executing and overseeing the corporate strategy of a rapidly growing medical device company. Dr. Essig also brings broad knowledge of the healthcare industry and deep capital markets, investment and financial services expertise. Dr since 2017.
| Age | 56 |
| Tenure | 7 years |
| Professional Marks | MBA |
| Address | One IDEXX Drive, Westbrook, ME, United States, 04092 |
| Phone | 207 556 0300 |
| Web | https://www.idexx.com |
IDEXX Laboratories Management Efficiency
The company has return on total asset (ROA) of 0.2283 % which means that it generated a profit of $0.2283 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.8074 %, meaning that it created $0.8074 on every $100 dollars invested by stockholders. IDEXX Laboratories' management efficiency ratios could be used to measure how well IDEXX Laboratories manages its routine affairs as well as how well it operates its assets and liabilities. At this time, IDEXX Laboratories' Return On Tangible Assets are fairly stable compared to the past year. Return On Assets is likely to rise to 0.27 in 2024, whereas Return On Capital Employed is likely to drop 0.26 in 2024. At this time, IDEXX Laboratories' Return On Assets are fairly stable compared to the past year.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Alan Spoon | Danaher | 69 | |
| Robert Epstein | Illumina | 62 | |
| Stanley Meresman | Guardant Health | 71 | |
| Arthur Bowman | Illumina | 69 | |
| Robert Ragusa | Twist Bioscience Corp | 58 | |
| Martiny Harris | Thermo Fisher Scientific | 59 | |
| Xiaoying Mai | Twist Bioscience Corp | 30 | |
| George Scangos | Agilent Technologies | 72 | |
| Gary Hendrickson | Waters | 64 | |
| Lars Sorensen | Thermo Fisher Scientific | 67 | |
| Francis deSouza | Illumina | 53 | |
| Gary Guthart | Illumina | 52 | |
| Susan Siegel | Illumina | 57 | |
| Rebecca Chambers | Illumina | N/A | |
| Nelson Chai | Thermo Fisher Scientific | 55 | |
| Daniel Bradbury | Illumina | 56 | |
| Nelson Chan | Twist Bioscience Corp | 57 | |
| David Walt | Illumina | 62 | |
| Tadataka Yamada | Agilent Technologies | 74 | |
| Michael Berendt | Waters | 71 | |
| Linda Filler | Danaher | 61 | |
Management Performance
| Return On Equity | 0.81 | ||||
| Return On Asset | 0.23 |
IDEXX Laboratories Leadership Team
Elected by the shareholders, the IDEXX Laboratories' board of directors comprises two types of representatives: IDEXX Laboratories inside directors who are chosen from within the company, and outside directors, selected externally and held independent of IDEXX. The board's role is to monitor IDEXX Laboratories' management team and ensure that shareholders' interests are well served. IDEXX Laboratories' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, IDEXX Laboratories' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kathy Turner, Corporate Vice President | ||
| Sophie Vandebroek, Director | ||
| Jonathan Ayers, Chairman, CEO and Pres | ||
| William End, Lead Independent Director | ||
| Jacqueline Studer, Corporate Vice President General Counsel, Secretary | ||
| Johnny Powers, Executive VP | ||
| Rebecca Henderson, Independent Director | ||
| Michael Lane, Corporate Vice President General Manager | ||
| Anne Szostak, Independent Director | ||
| George Fennell, Senior Officer | ||
| Sharon Underberg, Corporate Vice President General Counsel, and Corporate Secretary | ||
| Ken Grady, Senior Officer | ||
| Jay Mazelsky, Executive VP | ||
| Stuart Essig, Independent Director | ||
| M Szostak, Independent Director | ||
| Bruce Claflin, Independent Director | ||
| Sam Samad, Independent Director | ||
| Barry Johnson, Independent Director | ||
| Giovani Twigge, Chief Human Resource Officer, Corporate Vice President | ||
| Nimrata PE, Sector Strategy | ||
| Martin Smith, Executive CTO | ||
| Jeffery Chadbourne, Director Reporting | ||
| Daniel Junius, Independent Director | ||
| Lawrence Kingsley, Independent Director | ||
| Kerry Bennett, Senior Labs | ||
| Thomas Craig, Independent Director | ||
| Michael Johnson, Executive Officer | ||
| Jonathan Mazelsky, CEO President | ||
| James Polewaczyk, Executive Officer | ||
| John Hart, Senior Operations | ||
| Michael Williams, Executive VP | ||
| Pat Venters, Chief Marketing Officer, Vice President | ||
| Brian McKeon, CFO, Principal Accounting Officer, Executive VP and Treasurer |
IDEXX Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is IDEXX Laboratories a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.81 | ||||
| Return On Asset | 0.23 | ||||
| Profit Margin | 0.23 % | ||||
| Operating Margin | 0.27 % | ||||
| Current Valuation | 41.29 B | ||||
| Shares Outstanding | 83.05 M | ||||
| Shares Owned By Insiders | 0.92 % | ||||
| Shares Owned By Institutions | 92.56 % | ||||
| Number Of Shares Shorted | 1.76 M | ||||
| Price To Earning | 61.31 X |
IDEXX Laboratories Investors Sentiment
The influence of IDEXX Laboratories' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in IDEXX. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to IDEXX Laboratories' public news can be used to forecast risks associated with an investment in IDEXX. The trend in average sentiment can be used to explain how an investor holding IDEXX can time the market purely based on public headlines and social activities around IDEXX Laboratories. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
IDEXX Laboratories' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for IDEXX Laboratories' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average IDEXX Laboratories' news discussions. The higher the estimated score, the more favorable is the investor's outlook on IDEXX Laboratories.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards IDEXX Laboratories in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, IDEXX Laboratories' short interest history, or implied volatility extrapolated from IDEXX Laboratories options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in IDEXX Laboratories. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. For more information on how to buy IDEXX Stock please use our How to Invest in IDEXX Laboratories guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Complementary Tools for IDEXX Stock analysis
When running IDEXX Laboratories' price analysis, check to measure IDEXX Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IDEXX Laboratories is operating at the current time. Most of IDEXX Laboratories' value examination focuses on studying past and present price action to predict the probability of IDEXX Laboratories' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IDEXX Laboratories' price. Additionally, you may evaluate how the addition of IDEXX Laboratories to your portfolios can decrease your overall portfolio volatility.
| CEOs Directory Screen CEOs from public companies around the world | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Stocks Directory Find actively traded stocks across global markets | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |
Is IDEXX Laboratories' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of IDEXX Laboratories. If investors know IDEXX will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about IDEXX Laboratories listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.121 | Earnings Share 10.04 | Revenue Per Share 44.073 | Quarterly Revenue Growth 0.088 | Return On Assets 0.2283 |
The market value of IDEXX Laboratories is measured differently than its book value, which is the value of IDEXX that is recorded on the company's balance sheet. Investors also form their own opinion of IDEXX Laboratories' value that differs from its market value or its book value, called intrinsic value, which is IDEXX Laboratories' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because IDEXX Laboratories' market value can be influenced by many factors that don't directly affect IDEXX Laboratories' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between IDEXX Laboratories' value and its price as these two are different measures arrived at by different means. Investors typically determine if IDEXX Laboratories is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, IDEXX Laboratories' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.